0
1. 10. 2017.
Difference in biomarker profiles in heart failure with reduced and preserved ejection fraction
Introduction: Up to 50% of patients with acute heart failure (AHF) have preserved left ventricular ejection fraction (HFPEF group)1. Due to diverse activated pathophysiological pathways, there should be a difference in biomarkers release in heart failure with preserved ejection fraction (HFPEF) and reduced ejection fraction (HFREF). BNP is the best studied biomarker in AHF, but we want to investigate difference in release of troponin (marker of myocytes stress and injury), tumor marker CA125 (marker of congestion and volume overload om HF) and cystatin C (marker of interstitial fibrosis).